logo
Health harms linked to living near highly microplastic-polluted US coastlines, study finds

Health harms linked to living near highly microplastic-polluted US coastlines, study finds

CNN14 hours ago

Sign up for CNN's Life, But Greener newsletter. Our limited newsletter series guides you on how to minimize your personal role in the climate crisis — and reduce your eco-anxiety.
Living near heavily microplastic-polluted waters along the United States coastline may significantly raise the risk of developing type 2 diabetes, stroke and coronary artery disease, a condition in which plaque blocks the blood vessels feeding the heart, a new study found.
'This is one of the first large-scale studies to suggest that living near waters heavily polluted with microplastics may be linked to chronic health conditions,' said senior author Dr. Sarju Ganatra, medical director of sustainability and vice chair of research in the department of medicine at Lahey Hospital & Medical Center in Burlington, Massachusetts.
'While this study measured pollution in ocean water, pollution isn't limited to the sea. Microplastics are everywhere: in drinking water, in the food we eat, especially seafood, and even in the air we breathe,' Ganatra said in a statement.
Microplastics are polymer fragments that can range from less than 0.2 inch (5 millimeters) down to 1/25,000th of an inch (1 micrometer). Anything smaller is a nanoplastic that must be measured in billionths of a meter.
Such minuscule particles can invade individual cells and tissues in major organs, experts say, potentially interrupting cellular processes and depositing endocrine-disrupting chemicals such as bisphenols, phthalates, flame retardants, perfluoroalkyl and polyfluoroalkyl substances or PFAS, and heavy metals.
'The chemicals can be carried to your liver and your kidney and your brain and even make their way across the placental boundary and end up in an unborn child,' Sherri 'Sam' Mason, director of sustainability at Penn State Behrend in Erie, Pennsylvania, told CNN in an earlier interview.
A flurry of recent studies have discovered microplastics and nanoplastics in human brain tissue, the testes and the penis, human blood, lung and liver tissues, urine and feces, mother's milk, and the placenta.
In the first analysis to illustrate harm to human health, a March study found people with microplastics or nanoplastics in their carotid artery tissues were twice as likely to have a heart attack, stroke or die from any cause over the next three years than people who had none.
Coastal waters were considered heavily polluted if every 'bathtub' of ocean water contained 10 or more plastic particles, according to the study published Wednesday in the Journal of the American Heart Association.
Measurements of microplastic concentrations were taken by the National Centers for Environmental Information between 2015 and 2020 for the ocean waters within 200 nautical miles of 152 coastal counties along the Pacific Ocean, Atlantic Ocean and the Gulf of Mexico.
Researchers then compared disease prevalence in those counties with whether residents lived near low or very high concentrations of microplastics. That data was then adjusted for other contributing risk factors such as age, sex, race, ethnicity, access to physicians and socioeconomic status.
Compared with people who lived near waters with low levels of pollution — defined as seeing maybe 'one tiny plastic speck in 200 bathtubs of ocean water' — people who lived near highly polluted waters had an 18% higher prevalence of type 2 diabetes, a 9% higher risk of stroke and a 7% higher risk of coronary artery disease, the study found.
However, the study cannot prove a cause-and-effect relationship between nearby ocean microplastic levels that were only measured in water and the development of cardiometabolic diseases, Ganatra said.
'We also didn't measure plastic levels in residents of these counties, and we don't yet know the exact ways these particles may harm the body. So, while the findings are compelling, they should be a call for more in-depth research, not for making definitive conclusions,' Ganatra added.
The study has additional limitations, including lack of information on the chemicals microplastics contain, said Ria Devereux, an environmental research fellow for the Sustainability Research Institute of the University of East London via email.
Chemicals commonly used in plastic production have been found to pose health risks, including skin irritation, respiratory diseases, hormonal disruptions and certain cancers.
'The adverse effects of chemicals used in plastic production are particularly pronounced in the Gulf of Mexico, an area often referred to as 'Cancer Alley,'' said Devereux, who was not involved in the new research. 'This region experiences a higher-than-average incidence of cancer, diabetes, and respiratory diseases, which are concentrated in particular areas.
'The reason behind this is the concentration of petrochemical, petroleum and production plants involved in plastic production and an increase in the presence of chemicals used within the plastic production such as BPA and Phthalates,' she added.
Phthalates, which are found in consumer products such as food storage containers, shampoo, makeup, perfume and children's toys, may have contributed to more than 13% of all global mortality from heart disease in 2018 among men and women ages 55 through 64, according to an April study.
'Phthalates contribute to inflammation and systemic inflammation in the coronary arteries, which can accelerate existing disease and lead to acute events including mortality,' Dr. Leonardo Trasande, Jim G. Hendrick, M.D. Professor of Pediatrics and professor of population health at NYU Grossman School of Medicine, told CNN in a prior interview.
The chemical compound bisphenol A, or BPA, is an endocrine disruptor, affecting the hormones in the body, and fetuses and babies are especially vulnerable. The chemical compound has been linked to fetal abnormalities, low birth weight, and brain and behavior disorders in infants and children, as well as diabetes, heart disease, cancer and obesity in adults. One study even found erectile dysfunction in workers exposed to BPA.
While it's not yet possible to clean microplastics from the ocean, there are steps one can take to reduce exposure to chemicals from plastics.
'One is to reduce our plastic footprint by using stainless steel and glass containers, when possible,' Trasande previously told CNN.
'Avoid microwaving food or beverages in plastic, including infant formula and pumped human milk, and don't put plastic in the dishwasher, because the heat can cause chemicals to leach out,' he said.
In addition, check the recycling code on the bottom of packaging to find the plastic type, and avoid plastics with recycling code 3, which typically contain phthalates, Trasande said.
Cut down on the use of disposable plastics and bring reusable bags to the grocery store, suggests the Natural Resources Defense Council, an environmental advocacy group. Invest in a zippered fabric bag and ask the dry cleaner to return your clothes in that instead of those thin sheets of plastic. Bring a travel mug to the local coffee store for takeout and silverware to the office, cutting back on plastic cups and utensils.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Yahoo

time16 minutes ago

  • Yahoo

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) - Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and lenalidomide in the Phase 3 registration trial - This milestone represents the second approved indication for Monjuvi in the United States WILMINGTON, Del., June 18, 2025--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). "Patients living with relapsed or refractory FL have been waiting for new options that improve progression-free survival without substantial increase in side effects. Based on the data from the inMIND trial of Monjuvi, today's approval brings to this patient population the first CD-19 and CD20-targeted immunotherapy combination and a potential new treatment standard," said Hervé Hoppenot, Chief Executive Officer, Incyte. "This second U.S. approval for Monjuvi reinforces our commitment to advancing innovation for the lymphoma community." The Priority Review and FDA approval of the supplemental Biologics License Application (sBLA) for Monjuvi was based on data from the pivotal, randomized, double-blind, placebo-controlled Phase 3 inMIND trial evaluating the efficacy and safety of Monjuvi in combination with rituximab and lenalidomide in adult patients with relapsed or refractory FL. Data from the trial was featured in the Late-breaking Session (LBA-1) at the 2024 American Society of Hematology (ASH) Annual Meeting.1 The study met its primary endpoint demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment, which demonstrated 27.5% (N=273) of patients with an event in the Monjuvi group vs. 47.6% (N=275) of patients with an event in the control arm. Patients receiving Monjuvi in combination with rituximab and lenalidomide achieved a median PFS by investigator assessment of 22.4 months (95% CI, 19.2-not evaluable [NE]) compared to 13.9 months (95% CI, 11.5-16.4) in the control arm (hazard ratio [HR]: 0.43 [95% CI, 0.32-0.58]; P<0.0001). The PFS assessed by an Independent Review Committee (IRC) was consistent with investigator-based results. Median PFS by IRC was not reached (95% CI, 19.3-NE) in the Monjuvi group versus 16.0 months (95% CI, 13.9-21.1) in the control arm (HR: 0.41 [95% CI, 0.29-0.56]. The PFS benefit was consistent across prespecified patient subgroups, including number of previous lines of therapy. The safety of Monjuvi in patients with FL was evaluated in 546 patients in the inMIND trial. Serious adverse reactions occurred in 33% of patients who received Monjuvi in combination with rituximab and lenalidomide, including serious infections in 24% of patients (including pneumonia and COVID-19 infection). Other serious adverse reactions in ≥ 2% of patients included renal insufficiency (3.3%), second primary malignancies (2.9%), and febrile neutropenia (2.6%). Fatal adverse reactions occurred in 1.5% of patients, including from COVID-19, sepsis, and adenocarcinoma. The most common adverse reactions (≥ 20%) in recipients of Monjuvi, excluding laboratory abnormalities, were respiratory tract infections (including COVID-19 infection and pneumonia), diarrhea, rash, fatigue, constipation, musculoskeletal pain, and cough. The most common Grade 3 or 4 laboratory abnormalities (≥ 20%) were decreased neutrophils and decreased lymphocytes. "Follicular lymphoma is generally an indolent yet chronic cancer that frequently recurs after treatment, making long-term disease control a critical objective," said Christina Poh, M.D., Assistant Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Center. "The FDA approval of Monjuvi in combination with rituximab and lenalidomide marks a significant advancement, offering a chemotherapy-free option that has demonstrated a meaningful reduction in the risk of disease progression across a broad patient population, including those with high-risk disease." FL is the second most common type of non-Hodgkin lymphoma (NHL) and represents up to 30% of NHL cases.2 While considered an indolent, slow-growing disease with prolonged survival, FL is challenging to treat due to its tendency for frequent relapse, need for multiple lines of therapy and potential transformation into large B-cell lymphoma.2,3 "While the initial responses to FL treatment are often positive, recurrence can become increasingly difficult for patients to manage as they navigate emotions and the next treatment steps related to relapse," said Mitchell Smith, M.D., Ph.D., Chief Medical Officer, Follicular Lymphoma Foundation. "We are pleased that the FDA has approved tafasitamab, part of a treatment combination offering a new option for patients living with this chronic disease." In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication was approved under accelerated approval by the U.S. FDA based on overall response rate (ORR). Continued approval of Monjuvi for this indication may be contingent on verification and description of clinical benefit in confirmatory trial(s). Tafasitamab is also being evaluated as a therapeutic option in an ongoing pivotal trial for first-line DLBCL. Incyte is committed to supporting patients and removing barriers to access medicines. Eligible patients in the U.S. who are prescribed Monjuvi have access to IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering personalized patient support, including financial assistance and ongoing education and additional resources. More information about IncyteCARES is available by visiting or calling 1-855-452-5234, Monday through Friday, from 8 a.m. to 8 p.m. ET. About inMIND A global, double-blind, randomized, controlled Phase 3 study, inMIND (NCT04680052) evaluated the efficacy and safety of tafasitamab in combination with rituximab and lenalidomide compared with placebo in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma (FL) Grade 1 to 3a or relapsed or refractory nodal, splenic or extranodal marginal zone lymphoma (MZL). The study enrolled a total of 654 adults (age ≥18 years). The primary endpoint of the study is progression-free survival (PFS) by investigator assessment in the FL population, and the key secondary endpoints are PFS in the overall population as well as positron emission tomography complete response (PET-CR) and overall survival (OS) in the FL population. For more information about the study, please visit About Monjuvi® (tafasitamab-cxix) Monjuvi® (tafasitamab-cxix) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). MorphoSys and Incyte entered into: (a) in January 2020, a collaboration and licensing agreement to develop and commercialize tafasitamab globally; and (b) in February 2024, an agreement whereby Incyte obtained exclusive rights to develop and commercialize tafasitamab globally. In the U.S., Monjuvi is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). MONJUVI is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials. Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). In Europe, Minjuvi® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. XmAb® is a registered trademark of Xencor, Inc. Monjuvi, Minjuvi, the Minjuvi and Monjuvi logos and the "triangle" design are registered trademarks of Incyte. IMPORTANT SAFETY INFORMATION What are the possible side effects of MONJUVI? MONJUVI may cause serious side effects, including: Infusion reactions. Your healthcare provider will monitor you for infusion reactions during your infusion of MONJUVI. Tell your healthcare provider right away if you get fever, chills, rash, flushing, headache, or shortness of breath during an infusion of MONJUVI Low blood cell counts (platelets, red blood cells, and white blood cells). Low blood cell counts are common with MONJUVI, but can also be serious or severe. Your healthcare provider will monitor your blood counts during treatment with MONJUVI. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or any bruising or bleeding Infections. Serious infections, including infections that can cause death, have happened in people during treatment with MONJUVI and after the last dose. Tell your healthcare provider right away if you get a fever of 100.4 °F (38 °C) or above, or develop any signs or symptoms of an infection The most common side effects of MONJUVI when given with lenalidomide in people with DLBCL include: respiratory tract infection feeling tired or weak diarrhea cough fever swelling of lower legs or hands decreased appetite The most common side effects of MONJUVI when given with lenalidomide and rituximab in people with FL include: respiratory tract infections diarrhea rash feeling tired or weak muscle and bone pain constipation cough These are not all the possible side effects of MONJUVI. Your healthcare provider will give you medicines before each infusion to decrease your chance of infusion reactions. If you do not have any reactions, your healthcare provider may decide that you do not need these medicines with later infusions. Your healthcare provider may need to delay or completely stop treatment with MONJUVI if you have severe side effects. Before you receive MONJUVI, tell your healthcare provider about all your medical conditions, including if you Have an active infection or have had one recently Are pregnant or plan to become pregnant. MONJUVI may harm your unborn baby. You should not become pregnant during treatment with MONJUVI. Do not receive treatment with MONJUVI in combination with lenalidomide if you are pregnant because lenalidomide can cause birth defects and death of your unborn baby You should use an effective method of birth control (contraception) during treatment and for 3 months after your last dose of MONJUVI Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with MONJUVI Are breastfeeding or plan to breastfeed. It is not known if MONJUVI passes into your breastmilk. Do not breastfeed during treatment and for at least 3 months after your last dose of MONJUVI You should also read the lenalidomide Medication Guide for important information about pregnancy, contraception, and blood and sperm donation. Tell your healthcare provider about all the medications you take, including prescription and over- the-counter medicines, vitamins, and herbal supplements. Call your doctor for medical advice about side effects. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Incyte Medical Information at 1-855-463-3463. Please see the full Prescribing Information including the Medication Guide for Monjuvi. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether Monjuvi may provide a successful treatment option for patients with FL, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other regulatory authorities outside of the United States; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2024 and its quarterly report on form 10Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. ___________________________ 1 Sehn L H., et al. ASH Annual Meeting 2024; Late Breaking Abstract Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND). 2 National Center for Biotechnology Information. Follicular Lymphoma. Accessed March 7, 2025. 3 G. Gupta, et al. Am J Blood Res. 2022 Aug 15;12(4):105–124. View source version on Contacts Media media@ Investors ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Best sun hat for 2025 to keep your face and skin protected from UV rays
Best sun hat for 2025 to keep your face and skin protected from UV rays

Yahoo

time29 minutes ago

  • Yahoo

Best sun hat for 2025 to keep your face and skin protected from UV rays

With beach stays and pool days calling your name, it's time to stock up on all your summer faves — stylish sundresses, killer shades and the best sun hat to throw in your vacation luggage. But as you grab the gear that will support your outdoor adventures, it's important to remember that soaking up every last minute of summer fun shouldn't mean soaking up every last ray of summer sun. For one thing, avoiding sunburns is just smart living — they hurt! But more to the point, prolonged sun exposure on any of your skin, including your ears, the back of your neck and your scalp, can lead to serious and long-term health concerns, including premature skin aging, eye damage and skin cancer — the most common form of cancer in the United States. And while regular sunscreen application is one of the best ways to stave off the dangerous UV rays that are a significant contributor to the cellular damage that leads to melanoma and nonmelanoma skin cancers, according to some studies, hats and other sun protective clothing may be even more effective. "Skin cancer is more likely to develop on parts of the body that are exposed to the sun, such as the ears, nose, scalp, forehead and neck," explains Dr. Susan Taylor, a board-certified dermatologist and president of the American Academy of Dermatology. The vast majority of skin cancer is what's known as basal cell carcinoma, she says, and 85% of basal cell carcinomas occur on the head and neck region. The best way to lower your risk is to be proactive by applying sunscreen daily, using sunglasses and wearing sun protective clothing like hats. However, not all sun hats are created equally. "To get the most protection from the sun's harmful rays, be sure to choose a hat with a wide brim that shades your face, ears and neck," Taylor says. "These are the areas on your body that are most exposed to the sun." Dr. Rachel Nazarian, a board-certified dermatologist, concurs, adding that "the tighter the fabric weave, the better." With those tips in mind, you won't find any traditional baseball caps or beanies on this list (although in a pinch, some protection is always better than none!), and you'll also find we've prioritized options with ultraviolet protection factor (UPF) ratings that indicate a product has been verified to block out UV rays. With guidance from dermatologists and a lot of research and hands-on (heads-on) testing, we rounded up the best sun protection hats around for every preference and need. Best overall sun hat More sun hats we like for 2025 Factors to consider when purchasing a sun hat How we chose Other products we tested Meet the experts Sun hats might be a fun summer accessory, but choosing the right option goes beyond just finding something that looks good. Instead, there are a number of factors to take into consideration. Material: Different kinds of material have different benefits, particularly when it comes to sun protection. "Hats made from tightly woven fabrics, such as canvas, offer better protection than those with open weaves, like some straw hats, which allow sunlight through," says Taylor. According to Nazarian, polyester and nylon are two of the best synthetic fabrics you can choose. "They do a great job of blocking sunlight," she says. Not only are these materials tightly woven, they often come in darker colors. Weave density: While certain synthetic fabrics are inherently denser, that doesn't mean you can't opt for a hat made from straw or raffia. According to the experts, raffia is typically a better option than straw, but either can be fine as long as you make sure they have a high-density weave. "With straw and raffia, you can hold the hat up to the sun and see how much light comes through," says Chacon. "That will be your indicator of the amount of exposure." UPF rating: Another huge factor is the UPF rating, which indicates how much UV radiation a fabric absorbs. The higher the rating, the better the sun (and skin) protection. Look for a hat with a UPF rating of 50+, which is the highest option available. Coverage: Think about how much coverage the hat provides. "Avoid baseball caps, which leave your ears and neck exposed," says Taylor. Instead, opt for a wide-brimmed hat, ideally with a brim of at least 2 or 3 inches. Some hats also have additional neck coverage, which can be important depending on how long you plan to be outside. Color: According to Chacon, color absolutely matters when it comes to sun protection. "Dark colors offer more protection than light colors because they absorb more UV rays," she says. Bright colors can also be a good choice. Style: Finally, think about style and choose a hat you actually like. After all, if you don't like the way a hat looks, you probably aren't going to wear it! To find the best sun hats for summer, we consulted with three different experts, all board-certified in dermatology, to get a better understanding of what to look for in terms of sun protection. Using their expertise, we considered more than 20 different options from various companies to find the right hat for every style, price point and need. We tested the top contenders to verify their style, comfort, durability and effectiveness. Gigi Pip Ozzy Packable Straw Sun Hat: We loved the style and versatility of this cute straw hat, and it came close to being our top pick for women, but it lacks verified UPF protection and costs a pretty penny. Eric Javits Squishee Bucket: This hat has a lot going for it that we really love — UPF 50+ protection, a wide brim and a construction that you can fold or roll without ever losing the hat's shape. It's even super stylish, with a fun fringed edge and 10 different colors to choose from. The only reason it didn't make our list was its price — at almost $300, we couldn't justify the cost when there are so many other cute options at a fraction of the price. That said, if you're in the market for a high-quality sun hat that's perfect for travel or hanging out on the deck, this is a good choice. Dr. Susan Taylor, MD, FAAD, president of the American Academy of Dermatology Dr. Rachel Nazarian, MD, FAAD, board-certified dermatologist Dr. Anna Chacon, MD, board-certified dermatologist Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.

Air conditioning at Chicago's Weiss Memorial Hospital could take weeks to fix
Air conditioning at Chicago's Weiss Memorial Hospital could take weeks to fix

CBS News

time30 minutes ago

  • CBS News

Air conditioning at Chicago's Weiss Memorial Hospital could take weeks to fix

Administrators at Chicago's Weiss Memorial Hospital spoke for the first time Wednesday after busted air conditioners forced patients to be transferred for their own safety. It could be weeks until the hospital in the Uptown neighborhood admits patients again. Imagine being at a hospital for medical care and the temperature inside soars to 92 degrees. That is exactly what happened to patients at Weiss Memorial Hospital, at 4646 N. Marine Dr. near Chicago's lakefront, on Monday. The sweltering conditions reached the point where the hospital had to shut down inpatient care and evacuate 45 patients. It got so hot at Weiss this week that every single patient in the facility had to be discharged or moved to their sister hospital, West Suburban Medical Center in Oak Park. Andrea Saviozzi, executive director of nursing and clinical services at Weiss, said no patient care situations were affected — and the hospital was not evacuated in the middle of procedures such as surgical operations. "We canceled our surgeries for the day," Saviozzi said. "We stopped admitted patients on Monday." Since Weiss could not meet the mandated requirement of an inside temperature of 86 degrees or less, officials there had to shut down all inpatient care. "We are an acute care hospital, so we have an intensive care unit. We have an operating room, general medical floor, an inpatient psych unit — so we have all different types," Saviozzi said. "Our population generally is more older population." HVAC crews have been working nonstop to try to repair the cooling system at Weiss Memorial Hospital, which officials said should have been replaced decades ago. "This whole repair is going to cost us somewhere in the quarter of a million dollar range — money that we really, a safety net hospital, usually doesn't really have," said Weiss chief executive officer Dr. Monoj Pressad. Pressad said the hospital that Weiss is losing several million more dollars a day from not being able to bill for patient care, and that the repairs will be temporary — because the hospital needs a complete overhaul with an entire new HVAC system. "They started springing leaks, they would trip — so that has to be repaired," Pressad said. Pressad said a previous owner of Weiss kicked the can down the road when it came to maintenance and upgrades. "We have people here who have been here for 30, 40 years. They have noticed it," he said. "It has been going on for a long time, and there wasn't much investment done in that area." The hospital said only one of its four air conditioning systems is working. It still has cooling in the ER, and is still accepting people who walk into the ER — but those people are quickly being transferred to other facilities once they are stabilized. Officials say it could take weeks to get the system back up and running, because it is difficult to find replacement parts.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store